Clinical trial
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
NCT00087126 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00087126 |
|---|---|
| Title | Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer |
| Official title | A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug |
| Interventions | topotecan hydrochloride |
| Enrollment | 27 |
| Start date | Feb 1, 2005 |
| Primary completion | Jan 1, 2010 |
| First posted | Jul 12, 2004 |
| Last update posted | Jan 8, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: